TY  - GEN
AU  - Para,M F
AU  - Meehan,P
AU  - Holden-Wiltse,J
AU  - Fischl,M
AU  - Morse,G
AU  - Shafer,R
AU  - Demeter,L M
AU  - Wood,K
AU  - Nevin,T
AU  - Virani-Ketter,N
AU  - Freimuth,W W
TI  - ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team
SN  - 0066-4804
PY  - 1999///0623
KW  - Acquired Immunodeficiency Syndrome
KW  - drug therapy
KW  - Adult
KW  - Anti-HIV Agents
KW  - therapeutic use
KW  - CD4 Lymphocyte Count
KW  - Delavirdine
KW  - adverse effects
KW  - Dose-Response Relationship, Drug
KW  - Female
KW  - HIV-1
KW  - genetics
KW  - Humans
KW  - Male
KW  - RNA, Viral
KW  - blood
N1  - Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S
UR  - https://doi.org/10.1128/AAC.43.6.1373
ER  -